New York, June 13, 2013 -- Moody's Investors Service affirmed the A3 senior unsecured rating of Teva Pharmaceutical Industries Limited ("Teva") and its subsidiaries. Concurrently Moody's changed the rating outlook to negative from stable. The outlook change follows Teva's announcement that it will pay Pfizer $1.6 billion over the next 18 months in a settlement related to the Protonix litigation.
Vollständigen Artikel bei Moodys lesen